Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines.

Autor:	Van Coillie J; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands.; Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, the Netherlands., Pongracz T; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands., Šuštić T; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands.; Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, the Netherlands., Wang W; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands., Nouta J; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands., Le Gars M; Janssen Vaccines & Prevention B.V., Leiden, the Netherlands., Keijzer S; Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands., Linty F; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands.; Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, the Netherlands., Cristianawati O; Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands., Keijser JBD; Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands., Visser R; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands.; Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, the Netherlands., van Vught LA; Center for Experimental and Molecular Medicine, Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands.; Department of Intensive Care, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Slim MA; Center for Experimental and Molecular Medicine, Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands.; Department of Intensive Care, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands., van Mourik N; Center for Experimental and Molecular Medicine, Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands.; Department of Intensive Care, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Smit MJ; Department of Medical Microbiology, Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands., Sander A; Centre for Medical Parasitology, Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; AdaptVac Aps, Copenhagen, Denmark., Schmidt DE; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands., Steenhuis M; Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands., Rispens T; Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands., Nielsen MA; Centre for Medical Parasitology, Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Mordmüller BG; Department of Medical Microbiology, Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands., Vlaar APJ; Department of Intensive Care, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.; Laboratory of Experimental Intensive Care and Anaesthesiology, L.E.I.C.A., Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands., Ellen van der Schoot C; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands., Roozendaal R; Janssen Vaccines & Prevention B.V., Leiden, the Netherlands., Wuhrer M; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands., Vidarsson G; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands.; Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, the Netherlands.
Jazyk:	angličtina
Zdroj:	IScience [iScience] 2023 Aug 14; Vol. 26 (9), pp. 107619. Date of Electronic Publication: 2023 Aug 14 (Print Publication: 2023).
DOI:	10.1016/j.isci.2023.107619
Abstrakt:	IgG antibodies are important mediators of vaccine-induced immunity through complement- and Fc receptor-dependent effector functions. Both are influenced by the composition of the conserved N -linked glycan located in the IgG Fc domain. Here, we compared the anti-Spike (S) IgG1 Fc glycosylation profiles in response to mRNA, adenoviral, and protein-based COVID-19 vaccines by mass spectrometry (MS). All vaccines induced a transient increase of antigen-specific IgG1 Fc galactosylation and sialylation. An initial, transient increase of afucosylated IgG was induced by membrane-encoding S protein formulations. A fucose-sensitive ELISA for antigen-specific IgG (FEASI) exploiting FcγRIIIa affinity for afucosylated IgG was used as an orthogonal method to confirm the LC-MS-based afucosylation readout. Our data suggest that vaccine-induced anti-S IgG glycosylation is dynamic, and although variation is seen between different vaccine platforms and individuals, the evolution of glycosylation patterns display marked overlaps. Competing Interests: M.L.G. and R.R. are employees of Janssen Pharmaceuticals and M.L.G. is a shareholder in Johnson & Johnson. A.S. and W.A.d.J. are employees at AdaptVac, a company commercializing virus-like particle display technology and vaccines, including several patents. A.S., A.S., T.G.T., and M.N. are founders of AdaptVac and listed as coinventors on a patent covering the AP205 CLP vaccine platform technology (WO2016112921 A1) licensed to AdaptVac. Janssen Pharmaceuticals sponsored IgG glycosylation analysis at LUMC. Sanquin provided consultancy services to Janssen Pharmaceuticals during this study. All other authors declare they have no conflicts of interests. (© 2023 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu